Dr. Torti appointed to FDA leadership roles
The FDA announced the appointment of Frank M. Torti, MD, as its principal deputy commissioner and first chief scientist.
The FDA announced the appointment of Frank M. Torti, MD, as its principal deputy commissioner and first chief scientist.
Dr. Torti, who has written extensively on prostate and bladder cancer, is responsible for ensuring the quality and regulatory focus of the intramural research programs of the agency, with emphasis on clinical research trials.
He serves on the National Institutes of Health National Advisory Council for Complementary and Alternative Medicine, and is president of the Cancer Biology Training Consortium. He also is an NIH MERIT Award recipient.
Dr. Torti is the Charles L. Spurr Professor of Medicine, chair of the department of cancer biology, and director of the comprehensive cancer center at Wake Forest University School of Medicine in Winston-Salem, NC. He previously was on the faculty at Stanford University, Stanford, CA.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
